Australia's largest stock trading and investment forum Australia's #1 stock forum

VLA

Click for more information

0.00%

$1.75 viralytics limited

Incredulous, page-35

First 35 Last

Share
Profile

Follow
whytee

5,928 Posts.

311

23/02/18

18:54

Post #: 31301497
Share

Originally posted by milward ↑

The shareholders have been sold short..
Why did'nt Viralytics wait to release the clinical data from the keynote trail before
doing an agreement with merck.
I expect the data to be released to be outstanding and that would have given viralytics a much
better bargaining position.
whereby cavatek will have multiple uses in combination.A very attractive proposition to big pharma
with pd1 inhibitors.
The acquisition agreement will be finalised by the end of june.The keynote trail data is to released
2q2018 so the shareholders will have prior knowledge before deciding which way to vote.
Is it possible now that viralytics will delay releasing the keynote trial data until after the deadline for the acquistion.
If big pharma get access to outstanding keynote trial data before the vote then maybe a bid from another party.

Expand

I guess if holders like Cavatek enough they should consider investing in Merck...

VLA Price at posting: $1.70 Sentiment: Hold Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

ACW

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

MTM

Australian Rare Earths bullish on early-stage uranium potential at Overland, SA

MIN

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

WC8

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

There are more pages in this discussion • 63 more messages in this thread...

First 35 Last

Add VLA (ASX) to my watchlist